Hamostaseologie 2019; 39(03): 279-283
DOI: 10.1055/s-0039-1683974
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Management of Helicobacter pylori in Patients with Immune Thrombocytopenia

Yenny Alejandra Moreno Vanegas
1   Division of Hematology and Medical Oncology, Mayo Clinic Florida, Jacksonville, Florida, United States
,
Prakash Vishnu
1   Division of Hematology and Medical Oncology, Mayo Clinic Florida, Jacksonville, Florida, United States
› Author Affiliations
Further Information

Publication History

31 August 2018

07 February 2019

Publication Date:
19 March 2019 (online)

Abstract

There is an association between Helicobacter pylori infection and immune thrombocytopenia (ITP), and few studies have suggested that eradicative treatment of H. pylori infection may improve platelet counts in patients with ITP. Conventional treatments for ITP include immunosuppressive agents, and more recently thrombopoietic agents. However, based on clinical reports of association between H. pylori and ITP, several medical societies increasingly suggest detection and eradication of H. pylori as a treatment for ITP. In this article, we reappraise recent medical literature to determine the effectiveness of platelet response after treatment of H. pylori infection in patients with ITP. We searched two online databases (MEDLINE and Google Scholar) for full articles published between January 2008 and May 2018, and found a total of 11 studies that presented data and outcomes of treatment of H. pylori infection in ITP patients. All the studies administered triple therapy (amoxicillin 500 mg, clarithromycin 250 mg and a proton-pump inhibitor each given twice daily for either 7- or 14-day course) for eradication of H. pylori. Median overall platelet response ranged from 27 to 69.2% with a complete response rate ranging from 0 to 65.4% and a partial response rate ranging from 0 to 29.4%. Although there is variability in the effectiveness between different populations, it appears to be of benefit to ITP patients with concomitant H. pylori infection when treated with triple therapy. However, further studies to understand the pathogenesis of H. pylori-associated ITP is necessary for the development of new therapeutic approaches for ITP.

 
  • References

  • 1 Johnsen J. Pathogenesis in immune thrombocytopenia: new insights. Hematology (Am Soc Hematol Educ Program) 2012; 2012: 306-312
  • 2 Neunert C, Lim W, Crowther M, Cohen A, Solberg Jr L, Crowther MA. ; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117 (16) 4190-4207
  • 3 Shaikh KH, Ahmed S, Ayyub M, Anwar J. Association of Helicobacter pylori infection with idiopathic thrombocytopenic purpura. J Pak Med Assoc 2009; 59 (10) 660-663
  • 4 Cheng YS, Kuang LP, Zhuang CL, Jiang JD, Shi M. Effects of cytotoxin-associated gene A (CagA) positive Helicobacter pylori infection on anti-platelet glycoprotein antibody producing B cells in patients with primary idiopathic thrombocytopenic purpura (ITP). Pak J Med Sci 2015; 31 (01) 121-126
  • 5 Zehnder JL, Semple JW, Imbach P, Neufeld EJ, Buchanan GR, Cines DB. ; ICIS Study Group on Future Research in ITP. Future research in ITP: an ICIS consensus. Ann Hematol 2010; 89 (Suppl. 01) 19-23
  • 6 Fujimura K, Kuwana M, Kurata Y. , et al. Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. Int J Hematol 2005; 81 (02) 162-168
  • 7 Veneri D, De Matteis G, Solero P. , et al. Analysis of B- and T-cell clonality and HLA class II alleles in patients with idiopathic thrombocytopenic purpura: correlation with Helicobacter pylori infection and response to eradication treatment. Platelets 2005; 16 (05) 307-311
  • 8 Satoh T, Pandey JP, Okazaki Y. , et al. Single nucleotide polymorphism of interleukin-1beta associated with Helicobacter pylori infection in immune thrombocytopenic purpura. Tissue Antigens 2009; 73 (04) 353-357
  • 9 Hashino S, Mori A, Suzuki S. , et al. Platelet recovery in patients with idiopathic thrombocytopenic purpura after eradication of Helicobacter pylori . Int J Hematol 2003; 77 (02) 188-191
  • 10 Gasbarrini A, Franceschi F, Tartaglione R, Landolfi R, Pola P, Gasbarrini G. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori . Lancet 1998; 352 (9131): 878
  • 11 Rostami N, Keshtkar-Jahromi M, Rahnavardi M, Keshtkar-Jahromi M, Esfahani FS. Effect of eradication of Helicobacter pylori on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura: a controlled trial. Am J Hematol 2008; 83 (05) 376-381
  • 12 Jackson SC, Beck P, Buret AG. , et al. Long term platelet responses to Helicobacter pylori eradication in Canadian patients with immune thrombocytopenic purpura. Int J Hematol 2008; 88 (02) 212-218
  • 13 Stasi R, Sarpatwari A, Segal JB. , et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood 2009; 113 (06) 1231-1240
  • 14 Arnold DM, Bernotas A, Nazi I. , et al. Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review. Haematologica 2009; 94 (06) 850-856
  • 15 Corcoran PA, Atherton JC, Kerrigan SW. , et al. The effect of different strains of Helicobacter pylori on platelet aggregation. Can J Gastroenterol 2007; 21 (06) 367-370
  • 16 Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood 2009; 113 (26) 6511-6521
  • 17 Malfertheiner P, Megraud F, O'Morain CA. , et al; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017; 66 (01) 6-30
  • 18 Yang JC, Lu CW, Lin CJ. Treatment of Helicobacter pylori infection: current status and future concepts. World J Gastroenterol 2014; 20 (18) 5283-5293
  • 19 Kim H, Lee WS, Lee KH. , et al; CoOperative Study Group A for Hematology (COSAH). Efficacy of Helicobacter pylori eradication for the 1st line treatment of immune thrombocytopenia patients with moderate thrombocytopenia. Ann Hematol 2015; 94 (05) 739-746
  • 20 Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002; 346 (13) 995-1008
  • 21 Cines DB, Liebman H, Stasi R. Pathobiology of secondary immune thrombocytopenia. Semin Hematol 2009; 46 (01) (Suppl. 02) S2-S14
  • 22 Ohe M, Hashino S. Successful treatment with erythromycin for idiopathic thrombocytopenic purpura. Korean J Hematol 2011; 46 (02) 139-142
  • 23 Tag HS, Lee HS, Jung SH. , et al. Effects of Helicobacter pylori eradication in patients with immune thrombocytopenic purpura. Korean J Hematol 2010; 45 (02) 127-132
  • 24 Asahi A, Kuwana M, Suzuki H, Hibi T, Kawakami Y, Ikeda Y. Effects of a Helicobacter pylori eradication regimen on anti-platelet autoantibody response in infected and uninfected patients with idiopathic thrombocytopenic purpura. Haematologica 2006; 91 (10) 1436-1437
  • 25 Emilia G, Luppi M, Zucchini P. , et al. Helicobacter pylori infection and chronic immune thrombocytopenic purpura: long-term results of bacterium eradication and association with bacterium virulence profiles. Blood 2007; 110 (12) 3833-3841
  • 26 Sivapathasingam V, Harvey MP, Wilson RB. Helicobacter pylori eradication: a novel therapeutic option in chronic immune thrombocytopenic purpura. Med J Aust 2008; 189 (07) 367-370
  • 27 Kikuchi T, Kobayashi T, Yamashita T, Ohashi K, Sakamaki H, Akiyama H. Eight-year follow-up of patients with immune thrombocytopenic purpura related toH. pyloriinfection. Platelets 2011; 22 (01) 61-64
  • 28 Payandeh M, Sohrabi N, Zare ME, Kansestani AN, Hashemian AH. Platelet Count Response to Helicobacter pylori Eradication in Iranian Patients with Idiopathic Thrombocytopenic Purpura. Mediterr J Hematol Infect Dis 2012; 4 (01) e2012056
  • 29 Payandeh M, Raeisi D, Sohrabi N. , et al. Poor platelet Count Response to Helicobacter Pylori Eradication in Patients with Severe Idiopathic Thrombocytopenic Purpura. Int J Hematol Oncol Stem Cell Res 2013; 7 (03) 9-14
  • 30 Sultan S, Irfan SM, Kaker J, Hasan M. Efficacy of helicobacter pylori eradication as an upfront treatment of secondary immune thrombocytopenia: an experience from Pakistan. Med J Malaysia 2016; 71 (02) 53-56
  • 31 Sheema K, Ikramdin U, Arshi N, Farah N, Imran S. Role of. Gastroenterol Res Pract 2017; 2017: 9529752
  • 32 O’Neill CM, Weitz IC, O’Connell C, Liebman HA. Ethnic and racial difference in Helicobacter pylori infection in patients with immune thrombocytopenia treated at a major urban medical center. Platelets 2018; 1-5